New Launch21 Mar 2026, 02:31 pm
Torrent Pharma Launches Oral and Injectable Formulations of Semaglutide, Priced Affordably
AI Summary
Torrent Pharmaceuticals has announced the launch of its Semaglutide brands - Sembolic and Semalix - in India, in both oral and injectable formulations. This launch expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity. Torrent Pharma is the first Indian company to offer this treatment across oral and injectable formulations, giving healthcare professionals a holistic choice for treating patients. The GLP-1 (glucagon-like peptide-1) receptor agonists have been shown to be effective at decreasing haemoglobin A1c (HbA1c), promoting weight loss and reducing the risk of cardiovascular events.
Key Highlights
- Torrent Pharma launches oral and injectable formulations of Semaglutide in India
- First Indian company to offer oral and injectable Semaglutide
- Expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity
- GLP-1 receptor agonists effective at decreasing HbA1c, promoting weight loss and reducing cardiovascular risk
- Torrent Pharma ranked 5th in the Indian Pharmaceuticals Market